Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Sepsis Intoxication; Septic Male and female aged 18 to 60 years inclusive 2. Sepsis diagnosed according to ACCP / SCCM (no later than 24 hours from the time of diagnosis of sepsis to screening visit) (Annex 1: Sequence Diagnostic for SCCM / ESICM / ACCP / ATS / SIS) 3. Informed consent for participation in the study signed by subject's own hand. 4. The baseline value of the SOFA scale ≥ 2 points. Non-inclusion 1. The presence of any of the for severe sepsis by ACCP / SCCM (presence of signs of organ failure Annex 1: for diagnosis of sepsis SCCM / ESICM / ACCP / ATS / SIS) 2. Individual intolerance of the components of the study drug and the comparator; 3. Hypersensitivity to sodium lactate; 4. Intravenous infusions of lactate or sorbitol-containing products within 24 hours before enrollment; 5. Pregnancy or breast-feeding; 6. Severe renal dysfunction (creatinine is more than 300 μmol/l or estimated creatinine clearance is less than 30 ml/min); 7. Metabolic alkalosis; 8. Severe metabolic acidosis; 9. Intracerebral hemorrhage; 10. Any thromboembolism; 11. Decompensated cardiovascular failure; 12. Arterial hypertension III st; 13. Conditions associated with immunodeficiency (the use of cytostatics or system steroids, AIDS); 14. Extracellular hyperhydration or hypervolemia; 15. Severe renal insuffiency (with oliguria / anuria); 16. Hyperkalaemia; 17. Hypercalcemia; 18. Ascites associated with cirrhosis; 19. Conditions associated with increased lactate levels (hyperlactatemia > 2 mmol / l), including lactic acidosis, or impaired lactate uptake (including due severe hepatic insufficiency); 20. Concomitant therapy with cardiac glycosides  Infusion of the study drug or the comparator is started more than 12 hours after randomization; 2. Lack of data for sepsis (diagnosis not confirmed); 3. Withdrawal of the informed consent by the subject; 4. Investigator considers that the infusion therapy with either study drug or comparator may not be continued for safety reasons; 5. Development of conditions that prevent further use of the study drug/comparator before efficacy evaluation visit (Visit 3); 6. Subject needs concomitant therapy prohibited in the study before efficacy evaluation visit (Visit 3); 7. Development of conditions (including serious adverse events) which make it impossible to evaluate the primary endpoint; 8. Confirmation of pregnancy at any time of the study